Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT05319873
Title Ribociclib, Tucatinib, and Trastuzumab for the Treatment of HER2 Positive Breast Cancer
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Jonsson Comprehensive Cancer Center

Her2-receptor positive breast cancer


Carboplatin + Docetaxel + Pertuzumab + Trastuzumab

Ribociclib + Trastuzumab + Tucatinib

Fulvestrant + Ribociclib + Trastuzumab + Tucatinib

Age Groups: adult | senior
Covered Countries USA

No variant requirements are available.